Parkinson’s Disease: New Stem Cell Therapy Shows Promise in Clinical Trial | Keck Medicine of USC

For individuals living with Parkinson’s disease, a condition affecting over one million Americans, a new avenue of hope is emerging. Researchers are testing a novel approach involving the implantation of specially engineered stem cells directly into the brain, aiming to address the core issue of dopamine loss that characterizes the disease. Whereas current treatments can manage symptoms, they don’t halt or slow the disease’s progression. This early-stage clinical trial, underway at Keck Medicine of USC and two other US sites, represents a significant step toward potentially modifying the course of Parkinson’s.

Understanding Parkinson’s and the Role of Dopamine

Parkinson’s disease is a progressive neurological disorder, meaning its symptoms worsen over time. It’s intimately linked to a decline in dopamine, a crucial chemical messenger in the brain responsible for controlling movement, but as well playing a role in mood, memory, and other vital functions. As the brain cells that produce dopamine gradually die, the ability to regulate movement is compromised, leading to the familiar symptoms of tremors, muscle stiffness, and slowed motion. Approximately 90,000 new cases are diagnosed each year in the United States, highlighting the ongoing necessitate for effective treatments.

Reprogramming Cells for Dopamine Production

The innovative treatment being tested utilizes induced pluripotent stem cells, or iPSCs. Unlike embryonic stem cells, iPSCs are created by “reprogramming” adult cells – such as those from skin or blood – back to a versatile state where they can develop into various cell types within the body. “We believe that these iPSCs can reliably mature into dopamine-producing brain cells, and offer the best chance of jump-starting the brain’s dopamine production,” explains Dr. Xenos Mason, a neurologist at Keck Medicine and co-principal investigator of the study. This approach bypasses the ethical concerns associated with embryonic stem cells and offers a potentially limitless source of dopamine-producing cells. More information about iPSC technology can be found on the International Society for Stem Cell Research website.

The Surgical Procedure and Monitoring

The implantation procedure, led by neurosurgeon Dr. Brian Lee, involves creating a small opening in the skull to access the brain. Using magnetic resonance imaging (MRI) for precise guidance, the stem cells are carefully placed into the basal ganglia, the region of the brain responsible for coordinating movement. Following the operation, participants are closely monitored for 12 to 15 months to assess changes in symptoms and to watch for any potential side effects, such as dyskinesia (excessive involuntary movements) or infection. Researchers are planning to continue following patients for up to five years to evaluate the long-term effects of the treatment. The clinical trial is registered on ClinicalTrials.gov, providing further details about the study protocol.

Early Phase Trial and Fast-Track Designation

This is an early phase, or Phase 1, clinical trial, meaning its primary focus is on safety and determining the appropriate dosage. The trial currently involves 12 individuals with moderate to moderate-severe Parkinson’s disease. The stem cell therapy, known as RNDP-001, is being developed by Kenai Therapeutics, a biotechnology company specializing in neurological disorder treatments. Notably, the U.S. Food & Drug Administration (FDA) has granted the trial “fast-track designation,” a process designed to expedite the development and review of promising therapies for serious conditions. You can find more information about the FDA’s fast-track process on the FDA website.

What the Results Could Mean

Dr. Lee emphasizes the ultimate goal: “Our ultimate goal is to pioneer a technique that can repair patients’ motor function and offer them a better quality of life.” If successful, this approach could potentially slow the progression of Parkinson’s disease and restore lost motor function by replenishing dopamine levels in the brain. However, it’s crucial to understand that this is still early research. The trial is designed to assess safety and feasibility, and it will take time to determine whether the treatment is truly effective. It’s also important to note a potential conflict of interest: Dr. Mason has previously received an honorarium from Kenai Therapeutics.

Looking Ahead: Further Research and Potential Implications

The results of this Phase 1 trial will be critical in determining the next steps. If the treatment is found to be safe and shows promising signs of efficacy, larger Phase 2 and Phase 3 trials will be necessary to confirm these findings and evaluate the treatment’s effectiveness in a broader population. These later-stage trials will also help to identify the optimal dosage and delivery method. The field of stem cell therapy for neurological disorders is rapidly evolving, and this trial represents a significant contribution to our understanding of how these cells can be harnessed to treat debilitating conditions like Parkinson’s disease. Ongoing research and clinical trials are essential to translate these promising findings into effective treatments for patients.